Zoetis launches first-in-class equine leptospirosis vaccine; Gour teams with IDEXX on dog dermatitis drug; Jaguar inks development deal with Patheon;

> Zoetis ($ZTS) introduced Lepto EQ Innovator, the first USDA-approved equine-specific vaccine to prevent leptospirosis in horses. Article

> Gour Medical signed an agreement with IDEXX ($IDXX) to develop a recombinant monoclonal antibody for the treatment and prevention of atopic dermatitis in dogs. Release

> Jaguar Animal Health ($JAGX) signed a contract with Patheon for the development and manufacturing of crofelemer, an active ingredient in Canalevia, its lead prescription drug candidate for the treatment of diarrhea in dogs. Release

> The Center for Food Safety released a new report urging the FDA to improve its oversight of animal drugs and suggesting that some products on the market pose a threat to animals, people and the environment. Release

> Aratana Therapeutics ($PETX) announced it has refinanced a $15 million loan with a a $40 million senior secured credit facility consisting of a $35 million term loan and a $5 million revolving loan. Release

> Animalcare Group recorded sales growth of 5% year-over-year to GBP 13.5 million ($20.7 million) for the fiscal year ended June 30. Article

> Scientists at UC San Francisco have put out a call for hospitals to help stop the spread of antibiotics-resistant infections by not buying meat from producers that use the drugs to promote the growth of food animals. Release

> Researchers at Kansas State University have determined that reducing inflammation during the birthing process helps dairy cows recover more quickly and improves their production over time. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…